Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 17% Improvement Relative Risk Desbois et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 199 patients in France Study underpowered to detect differences Desbois et al., Research Square, doi:10.21203/ Favors HCQ Favors control
Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis
Desbois et al., Research Square, doi:10.21203/ (Preprint)
Desbois et al., Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis, Research Square, doi:10.21203/ (Preprint)
Jul 2020   Source   PDF  
  All Studies   Meta
Retrospective 199 sarcoidosis patients showing non-statistically significant HCQ RR 0.83, p=1.0.
risk of case, 16.9% lower, RR 0.83, p = 1.00, treatment 3 of 27 (11.1%), control 23 of 172 (13.4%), NNT 44.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Desbois et al., 20 Jul 2020, retrospective, France, preprint, mean age 58.8, 13 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis Anne-Claire Desbois Hopital Universitaire Pitie Salpetriere Cindy Marques (  ) Hopital Universitaire Pitie Salpetriere Leila Lefèvre Hopital Universitaire Pitie Salpetriere Serge Barmo Hopital Universitaire Pitie Salpetriere Camille Lorenzo Hopital Universitaire Pitie Salpetriere Mathilde Leclercq Hopital Universitaire Pitie Salpetriere Gaëlle Leroux Hopital Universitaire Pitie Salpetriere Chloé Comarmond Hopital Universitaire Pitie Salpetriere Catherine Chapelon Hopital Universitaire Pitie Salpetriere Fanny Domont Hopital Universitaire Pitie Salpetriere Mathieu Vautier Hopital Universitaire Pitie Salpetriere David Saadoun Hopital Universitaire Pitie Salpetriere Patrice Cacoub Hopital Universitaire Pitie Salpetriere Research article Keywords: sarcoidosis, COVID-19, SARS-CoV-2 Posted Date: July 20th, 2020 DOI: License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License 1 Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with 2 sarcoidosis 3 Anne-Claire Desbois*1,2,3, Cindy Marques*1,2,3, Leila Lefèvre2,3, Serge Barmo2,3, Camille 4 Lorenzo2,3, Mathilde Leclercq2,3, Gaëlle Leroux2,3, Chloé Comarmond1,2,3, Catherine 5 Chapelon-Abric2,3, Fanny Domont2,3, Mathieu Vauthier2,3, David Saadoun1,2,3, Patrice 6 Cacoub1,2,3 7 * equal contribution 8 9 1. Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology- 10 Immunopathology- Immunotherapy (I3); F-75005, Paris, France; 11 2. Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU 12 i2B), Hôpital Pitié-Salpêtrière, AP-HP, F-75651, Paris, France; 13 3. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical 14 Immunology, F-75013, Paris, France, Centre national de référence des Maladies 15 Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares 16 17 Correspondence: Anne-Claire Desbois, MD, PhD, Department of Internal Medicine and 18 Clinical Immunology, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l’Hôpital, 75013 Paris. 19 Phone: + (33)(1) 42 17 80 68. Fax: + (33)(1) 42 17 80 33. 20 E 21 22 Conflict of interest: The authors have declared that no conflict of interest exists. 23 24 Word Count: 1496 words, 10 217 characters (including spaces), 2 tables, 20 references. 25 26 27 Declarations 28 The study was approved by our institutional ethics review board "Ethics committee of 29 research in Sorbonne University". All patients gave informed consent. Ethics approval and consent to participate: 30 31 Consent for publication: 32 Not applicable. 33 34 Availability of data and materials: 35 The datasets used and/or analyzed during the current study are available from the 36 corresponding author on reasonable request. 37 38 Competing interests: 39 The authors declare that they have no competing interests. 40 41 Funding: 42 The authors declare that they have no source of funding. 43 44 Authors' contributions: 45 ACD contributed to the conception and design of the work. 46 ACD and CM wrote the manuscript. 47 ACD, CM, LL, SB, CL, ML, GL, CC, CCA, FD, MV and DS collected the data. 48 CM have drafted the work 49 PC supervised the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop